All In Biotech

Drug Trial Radar · NCT06925581

A Trial of HRS-6768 in Patients With Advanced Solid Tumors

A Phase I/II Clinical Trial to Evaluate the Pharmacokinetics, Radiation Dosimetry, Safety and Preliminary Efficacy of HRS-6768 in the Treatment of Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Apr 24, 2025

Primary completion

Apr 2026

Study completion Apr 2027

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HRS-6768Drug

    HRS-6768

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1:Dose-limiting toxicity (DLTs)Time frame: From first dose of study drug through at least 6 weeks
  2. Phase 1: recommended Phase 2 dose (RP2D)Time frame: From first dose of study drug to end of phase 1 treatment (up to approximately 1 years)
  3. Phase 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) of HRS-6768Time frame: From first dose of study drug to end of treatment (up to approximately 2 years)
  4. Phase 2: Progression-free survival (PFS)Time frame: From first dose of study drug until disease progression or end of treatment (up to approximately 2 years)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Gaobo Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.